Educational research platform — not medical or investment advice. Verify all data before decisions.

ALT · NASDAQ

Altimmune

Clinical-stage biotech developing pemvidutide for obesity and metabolic dysfunction-associated steatohepatitis.

HQ Gaithersburg, MD, USA
Market cap Micro
Focus GLP-1/glucagon dual agonists
Investor relations ↗
Last updated:Jul 15, 2026Source:SEC EDGAR + company IRVerified:Reviewed against latest filingsData provider:PeptidePlanet Research

Overview

Pipeline programs

2

Active trials

1

Upcoming catalysts

1

Indications

2
ObesityMASH

AI research summary

Generated on demand from verified profile data.

The AI summarizer only sees the verified fields on this page. Every numbered citation maps to a source in the legend below.

Pipeline

1

Clinical trials

1

Upcoming catalysts

1
  • Aug 20, 2026

    Pemvidutide MASH Phase 2 window

    Readout · Window

    Source ↗

Timeline

Merged approvals, trial milestones, and catalysts. Newest first.

2

  1. Aug 20, 2026 · Corporate

    Pemvidutide MASH Phase 2 window

    Source ↗

  2. Apr 01, 2026 · Trial Milestone

    Phase 2 · IMPACT — pemvidutide in MASH — primary completion (recruiting)

    ClinicalTrials.gov ↗

Verified sources

  1. [1]
    Altimmune IR — Altimmune, Inc.retrieved 2026-07-15
  2. [2]
    SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
  3. [3]
    ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15

SEC filings search: EDGAR ↗

More companies

LLY

Eli Lilly

Incretin therapies (GLP-1 / GIP / glucagon triagonists)

NVO

Novo Nordisk

GLP-1 analogs, amylin, and combination peptides

AMGN

Amgen

Bispecific peptide antibody conjugates

VKTX

Viking Therapeutics

Dual GLP-1/GIP receptor agonists